Research progress on the interaction between tuberculosis and COVID-19

doi:10.19983/j.issn.2096-8493.2024045

Abstract

Abstract:

Tuberculosis (TB) was one of the major respiratory infectious diseases threatening public health before the corona virus disease-2019 (COVID-19) pandemic. TB and COVID-19 have a common pathogenic pathway, mainly transmitted through respiratory droplets, and their clinical characteristics were similar. Co-infection of the two infectious diseases can cause a double burden, which not only aggravating the severity of COVID-19, but also worsening active TB, and even causing cytokine storms, leading to severe respiratory diseases and increasing the risk of death of patients. The COVID-19 pandemic also posed a serious challenge to the public health care system, significantly interfering with the health care services provided for TB patients, and further increasing the incidence and mortality of TB patients globally. Therefore, the authors provides a review of the research progress on the interactions between COVID-19 and TB, with the aim of providing reference for clinical research, diagnosis and treatment.

Key words: Tuberculosis, Coronavirus infections, Comorbidity, Review literature as topic

CLC Number:

He Fanyi, Lu Nihong, Du Yingrong. Research progress on the interaction between tuberculosis and COVID-19[J]. Journal of Tuberculosis and Lung Disease , 2024, 5(4): 345-351. doi: 10.19983/j.issn.2096-8493.2024045

Figures/Tables 1

References 60

[1]	涂娇琴, 史娇阳, 范涛, 等. 妊娠合并新型冠状病毒肺炎的临床特点及管理策略. 国际医药卫生导报, 2022, 28(9):1243-1246. doi:10.3760/cma.j.issn.1007-1245.2022.09.014.
[2]	李兰娟, 任红. 传染病学. 9版. 北京: 人民卫生出版社, 2018: 212-219.
[3]	Bagcchi S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe, 2023, 4(1):e20. doi:10.1016/S2666-5247(22)00359-7.
[4]	Saunders MJ, Evans CA. COVID-19, tuberculosis and poverty: preventing a perfect storm. Eur Respir J, 2020, 56(1):2001348. doi:10.1183/13993003.01348-2020.
[5]	Tadolini M, Codecasa LR, Garcí a-García JM, et al. Active Tuberculosis, Sequelae and COVID-19 Co-Infection: First Cohort of 49 Cases. Eur Respir J, 2020, 56(1):2001398. doi:10.1183/13993003.01398-2020.
[6]	World Health Organization. Number of COVID-19 deaths reported to WHO[EB/OL]. [2024-06-02]. https://data.who.int/dashboards/covid19/deaths?n=c.
[7]	Pai M, Kasaeva T, Swaminathan S. Covid-19’s devastating effect on tuberculosis care-A path to recovery. N Engl J Med, 2022, 386(16):1490-1493. doi:10.1056/NEJMp2118145.
[8]	Jassat W, Cohen C, Tempia S, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV, 2021, 8(9):e554 -e567. doi:10.1016/S2352-3018(21)00151-X.
[9]	Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis, 2021, 73(7):e2005-e2015. doi:10.1093/cid/ciaa1198.
[10]	Motta I, Centis R, D’Ambrosio L, et al. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology, 2020, 26(4):233-240. doi:10.1016/j.pulmoe.2020.05.002. pmid: 32411943
[11]	Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?. J Microbiol Immunol Infect, 2020, 53(4):505-512. doi:10.1016/j.jmii.2020.05.013.
[12]	du Bruyn E, Stek C, Daroowala R, et al. Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa. Nat Commun, 2023, 14(1):188. doi:10.1038/s41467-022-35689-1. pmid: 36635274
[13]	Vergori A, Boschini A, Notari S, et al. SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak. Viruses, 2022, 14(7):1575. doi:10.3390/v14071575.
[14]	Wang Y, Feng R, Xu J, et al. An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol, 2021, 93(10):5682-5686. doi:10.1002/jmv.27119. pmid: 34061374
[15]	Shah VK, Firmal P, Alam A, et al. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Front Immunol, 2020, 11:1949. doi:10.3389/fimmu.2020.01949. pmid: 32849654
[16]	Vetter P, Eberhardt CS, Meyer B, et al. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series. mSphere, 2020, 5(6):e00827-20. doi:10.1128/mSphere.00827-20.
[17]	Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics, 2021, 11(1):316-329. doi:10.7150/thno.49713. pmid: 33391477
[18]	Agrati C, Carsetti R, Bordoni V, et al. The immune response as a double-edged sword: the lesson learnt during the COVID-19 pandemic. Immunology, 2022, 167(3):287-302. doi:10.1111/imm.13564. pmid: 35971810
[19]	Murdaca G, Di Gioacchino M, Greco M, et al. Basophils and Mast Cells in COVID-19 Pathogenesis. Cells, 2021, 10(10):2754. doi:10.3390/cells10102754.
[20]	Liu Q, Chi S, Dmytruk K, et al. Coronaviral infection and interferon response: the virus-host arms race and COVID-19. Viruses, 2022, 14(7):1349. doi:10.3390/v14071349.
[21]	Ramasamy S, Subbian S. Critical Determinants of Cytokine Storm and Type Ⅰ Interferon Response in COVID-19 Pathogenesis. Clin Microbiol Rev, 2021, 34(3):e00299-20. doi:10.1128/CMR.00299-20.
[22]	Torrelles JB, Schlesinger LS. Integrating Lung Physiology, Immunology, and Tuberculosis. Trends Microbiol, 2017, 25 (8):688-697. doi:10.1016/j.tim.2017.03.007. pmid: 28366292
[23]	Mayer-Barber KD, Barber DL. Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection. Cold Spring Harb Perspect Med, 2015, 5(12): a018424. doi:10.1101/cshperspect.a018424.
[24]	Taha RA, Kotsimbos TC, Song YL, et al. IFN-gamma and IL-12 are increased in active compared with inactive tuberculosis. Am J Respir Crit Care Med, 1997, 155(3):1135-1139. doi:10.1164/ajrccm.155.3.9116999.
[25]	Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum Dis, 2002, 2(Suppl 2):ii54-ii58. doi:10.1136/ard.61.suppl_2.ii54.
[26]	Simmons JD, Stein CM, Seshadri C, et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat Rev Immunol, 2018, 18(9):575-589. doi:10.1038/s41577-018-0025-3. pmid: 29895826
[27]	Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol, 2002, 168 (9):4620-4627. doi:10.4049/jimmunol.168.9.4620. pmid: 11971010
[28]	McCaffrey EF, Donato M, Keren L, et al. The immunoregulatory landscape of human tuberculosis granulomas. Nat Immunol, 2022, 23(2):318-329. doi:10.1038/s41590-021-01121-x. pmid: 35058616
[29]	Fatima S, Kumari A, Das G, et al. Tuberculosis vaccine: a journey from BCG to present. Life Sci, 2020, 252:117594. doi:10.1016/j.lfs.2020.117594.
[30]	Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond), 2020, 52(12):902-907. doi:10.1080/23744235.2020.1806353.
[31]	Dheda K, Perumal T, Moultrie H, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patientlevel impact, clinical presentation, and corrective interventions. Lancet Respir Med, 2022, 10(6):603-622. doi:10.1016/S2213-2600(22)00092-3.
[32]	Gao Y, Liu M, Chen Y, et al. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. J Med Virol, 2021, 93(1):194-196. doi:10.1002/jmv.26311.
[33]	TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 coinfection: description of the global cohort. Eur Respir J, 2022, 59(3):2102538. doi:10.1183/13993003.02538-2021.
[34]	Mousquer GT, Peres A, Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace. Tuberculosis (Edinb), 2021, 126:102020. doi:10.1016/j.tube.2020.102020.
[35]	Stochino C, Villa S, Zucchi P, et al. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J, 2020, 56(1):2001708. doi:10.1183/13993003.01708-2020.
[36]	Starshinova AA, Kudryavtsev I, Malkova A, et al. Molecular and Cellular Mechanisms of M.tuberculosis and SARS-CoV-2 Infections-Unexpected Similarities of Pathogenesis and What to Expect from Co-Infection. Int J Mol Sci, 2022, 23(4):2235. doi:10.3390/ijms23042235.
[37]	Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol, 2013, 3:411. doi:10.3389/fimmu.2012.00411.
[38]	Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2 Infection. N Engl J Med, 2020, 383(9):885-886. doi:10.1056/NEJMc2013020.
[39]	Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy, 2020, 75(7):1564-1581. doi:10.1111/all.14364. pmid: 32396996
[40]	Tapela K, Ochieng’ Olwal C, Quaye O. Parallels in the pathogenesis of SARS-CoV-2 and M.Tuberculosis: a synergistic or antagonistic alliance?. Future Microbiol, 2020, 15:1691-1695. doi:10.2217/fmb-2020-0179.
[41]	Shah T, Shah Z, Yasmeen N, et al. Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection. Front Immunol, 2022, 13:909011. doi:10.3389/fimmu.2022.909011.
[42]	Pinheiro DO, Pessoa MSL, Lima CFC, et al. Tuberculosis and coronavirus disease 2019 coinfection. Rev Soc Bras Med Trop, 2020, 53:e20200671. doi:10.1590/0037-8682-0671-2020.
[43]	Shariq M, Sheikh JA, Quadir N, et al. COVID-19 and Tuberculosis: the double whammy of respiratory pathogens. Eur Respir Rev, 2022, 31(164):210264. doi:10.1183/16000617.0264-2021.
[44]	Oei W, Nishiura H. The relationship between tuberculosis and influenza death during the influenza (H1N1) pandemic from 1918-19. Comput Math Methods Med, 2012, 2012:124861. doi:10.1155/2012/124861.
[45]	Moorlag SJCFM, Arts RJW, van Crevel R, et al. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect, 2019, 25(12):1473-1478. doi:10.1016/j.cmi.2019.04.020.
[46]	Covián C, Fernández-Fierro A, Retamal-Díaz A, et al. BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design. Front Immunol, 2019, 10:2806. doi:10.3389/fimmu.2019.02806. pmid: 31849980
[47]	Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th 17 responses and innate trained immunity. J Innate Immun, 2014, 6(2):152-158. doi:10.1159/000355628. pmid: 24192057
[48]	Netea MG, Joosten LA, Latz E, et al. Trained Immunity: A Program of Innate Immune Memory in Health and Disease. Science, 2016, 352(6284):aaf1098. doi:10.1126/science.aaf1098.
[49]	Chowdhury UN, Faruqe MO, Mehedy M, et al. Effects of Bacille Calmette Guerin (BCG) vaccination during COVID-19 infection. Comput Biol Med, 2021, 138:104891. doi:10.1016/j.compbiomed.2021.104891.
[50]	O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19?. Nat Rev Immunol, 2020, 20(6):335-337. doi:10.1038/s41577-020-0337-y. pmid: 32393823
[51]	Urashima M, Otani K, Hasegawa Y, et al. BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study. Int J Environ Res Public Health, 2020, 17(15):5589. doi:10.3390/ijerph17155589.
[52]	Wickramasinghe D, Wickramasinghe N, Kamburugamuwa SA, et al. Correlation Between Immunity From BCG and the Morbidity and Mortality of COVID-19. Trop Dis Travel Med Vaccines, 2020, 6:17. doi:10.1186/s40794-020-00117-z. pmid: 32868985
[53]	Mehta P, McAuley DF, Brown M, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet, 2020, 395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0. pmid: 32192578
[54]	Deshmukh R, Harwansh RK, Garg A, et al. COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2. Curr Genomics, 2024, 25(2):69-87. doi:10.2174/0113892029291098240129113500.
[55]	Rajamanickam A, Pavan Kumar N, Chandrasekaran P, et al. Effect of SARS-CoV-2 seropositivity on antigen-specific cytokine and chemokine responses in latent tuberculosis. Cytokine, 2022, 150:155785. doi:10.1016/j.cyto.2021.155785.
[56]	Tadolini M, García-García JM, Blanc FX, et al. On Tuberculosis and COVID-19 co-infection. Eur Respir J, 2020, 56(2):2002328. doi:10.1183/13993003.02328-2020.
[57]	Ruhwald M, Carmona S, Pai M. Learning from COVID-19 to reimagine tuberculosis diagnosis. Lancet Microbe, 2021, 2(5):e169 -e170. doi:10.1016/S2666-5247(21)00057-4.
[58]	WHO Rapid Evidence Appraisal for COVID-19 Therapies REACT Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA, 2020, 324(13): 1330-1341. doi:10.1001/jama.2020.17023.
[59]	Tang W, Leonhardt L, Pervez A, et al. A Case of Pleural Tuberculosis vs Latent Tuberculosis Reactivation as a Result of COVID-19 Infection and Treatment. J Community Hosp Intern Med Perspect, 2022, 12(4):89-93. doi:10.55729/2000-9666.1078.
[60]	Gopalaswamy R, Subbian S. Corticosteroids for COVID-19 therapy: potential implications on tuberculosis. Int J Mol Sci, 2021, 22(7):3773. doi:10.3390/ijms22073773.